ライフサイエンスコーパス: overtreatment

1 ostate cancer mortality) and minimize costs (overtreatment).

2 ates of re-excision, radical resections, and overtreatment.

3 native therapy or who may be spared possible overtreatment.

4 gement and ultimately increasing the risk of overtreatment.

5 ent infections while simultaneously limiting overtreatment.

6 e effects, and the risk of overdiagnosis and overtreatment.

7 has led to concerns about overdiagnosis and overtreatment.

8 y minimizing the inconveniences and costs of overtreatment.

9 d by screening, leading to overdiagnosis and overtreatment.

10 ncer has raised concerns about potential for overtreatment.

11 overdiagnosis and, if unrecognised, possible overtreatment.

12 ve malaria treatment without increasing NMFI overtreatment.

13 tion about CPM is needed to reduce potential overtreatment.

14 t outputs, but may significantly reduce NMFI overtreatment.

15 with moderate-dose statins while minimizing overtreatment.

16 carcinoma is not accurate enough to prevent overtreatment.

17 come symptomatic (overdiagnosis), leading to overtreatment.

18 identify indolent tumors are needed to avoid overtreatment.

19 apy decisions to improve outcomes and reduce overtreatment.

20 tantial potential risk for overdiagnosis and overtreatment.

21 ears to reduce the risk of PCSM with minimal overtreatment.

22 lives, there are growing concerns regarding overtreatment.

23 lacing the public at risk of overtesting and overtreatment.

24 d with prostate cancer screening, other than overtreatment?

25 se is of utmost significance, as it prevents overtreatment and adverse effects in patients.

26 erplasia include avoidance of glucocorticoid overtreatment and control of sex hormone imbalances.

27 of (18)F-FET PET has the potential to avoid overtreatment and corresponding costs, as well as unnece

28 ions have motivated lingering concerns about overtreatment and failure to involve women in treatment

29 losis treatment, which indicates substantial overtreatment and limited undertreatment.

30 decision making is fundamental to preventing overtreatment and promoting high-value, individualized p

31 s an appealing strategy for the reduction of overtreatment and secondary adverse effects.

32 ble therapy for individuals and avoidance of overtreatment and undertreatment of patients with conven

33 me INSS stage 1 patients (1) are at risk for overtreatment, and (2) have poor-prognostic biologic fin

34 to individualize glycemic goals and prevent overtreatment, and can serve as a template for applying

35 eutical marketing can lead to overdiagnosis, overtreatment, and overuse of medications.

36 to identify factors predictive of adherence, overtreatment, and undertreatment.

37 and indirect evidence that overdiagnosis and overtreatment are likely to be substantial with populati

38 o a 35% decrease (95% UI:31.2-39.8%) in NMFI overtreatment, but also a 19.5% reduction (95% UI:11-27.

39 n important option to reduce prostate cancer overtreatment, but it remains underutilized in many coun

40 nagement would have hypothetically decreased overtreatment by 94%, eliminating a median of 44 overtre

41 surgeon-led initiatives to address potential overtreatment can reduce the burden of surgical manageme

42 le range, 43-47) per patient and 2,169 total overtreatment days (95% confidence interval, 1,938-2,400

43 treatment by 94%, eliminating a median of 44 overtreatment days (interquartile range, 43-47) per pati

44 g the new model to indicate aRT might reduce overtreatment, decrease unnecessary adverse effects, and

45 rtality; and harms, including overdiagnosis, overtreatment, diagnostic procedure-related harms, fear,

46 herapy and to monitor their response so that overtreatment does not completely abrogate host defense

47 nt controversies surrounding prostate cancer overtreatment emphasize the critical need to delineate t

48 In just 6 categories of waste--overtreatment, failures of care coordination, failures i

49 We examined possible overtreatment for patients >/=18 years of age by examini

50 to therapies that would otherwise result in overtreatment for some patients.

51 rue disease, overtesting, overdiagnosis, and overtreatment have become common.

52 my or radiation therapy has been shown to be overtreatment in 30% of patients.

53 rategy could help to avoid overdiagnosis and overtreatment in patients with Barrett's oesophagus.

54 quality of care, has the potential to halve overtreatment in public and mission health facilities in

55 The high rate of overtreatment in the population studied carries both fin

56 However, overtreatment in the see-and-treat strategy has been rep

57 To limit overtreatment in these cases, minimally invasive limited

58 nefit from neo-adjuvant therapy and to avoid overtreatment in those patients who can proceed directly

59 AS represents a strategy to mitigate overtreatment in young patients with low-risk PCa in the

60 Overtreatment, in an attempt to reduce symptoms, can be

61 Overdetection and overtreatment is common in many areas of modern medicine

62 Overtreatment is pervasive in medicine and leads to pote

63 Overtreatment may be a growing problem, especially among

64 Range of overtreatment narrowed to 4.0-23.5% for those with norma

65 On the basis of concerns regarding overtreatment of biologically indolent cancers, focal ab

66 tifying children with malaria, and that much overtreatment of children without parasitaemia could be

67 may provide an opportunity to further reduce overtreatment of disease that is unlikely to progress to

68 Recent recognition of the overdiagnosis and overtreatment of ductal carcinoma in situ (DCIS) detecte

69 e most adequate treatment, thus avoiding the overtreatment of frail patients and the undertreatment o

70 Overtreatment of heparin-induced thrombocytopenia in the

71 Overtreatment of indolent disease also results in signif

72 ce early detection of aggressive disease and overtreatment of indolent disease.

73 prostate cancer (PC) are suboptimal, causing overtreatment of indolent PC and risk of delayed treatme

74 to guide clinical decision-making and avoid overtreatment of indolent PC and undertreatment of aggre

75 Overdiagnosis and overtreatment of indolent prostate cancer (PCA) is a ser

76 eatment selection, but the data suggest both overtreatment of low-risk disease and undertreatment of

77 stratification are urgently needed to avoid overtreatment of low-risk patients and to prioritize alt

78 Overdiagnosis and overtreatment of Lyme disease are associated with inappr

79 nsequences associated with overdiagnosis and overtreatment of Lyme disease, although previously recog

80 as been proposed as an approach for reducing overtreatment of malaria in the current era of widesprea

81 according to an algorithm designed to avoid overtreatment of mild disease and to accelerate treatmen

82 es treated with ACT, but also an increase in overtreatment of NMFI, with 70% NMFI cases (95% UI:56.4-

83 s causing a high degree of overdiagnosis and overtreatment of otherwise clinically insignificant case

84 t because of high rates of overdiagnosis and overtreatment of otherwise indolent tumors.

85 ing a therapeutic algorithm may lead to less overtreatment of patients and cost savings.

86 of a time frame for reevaluation lead to the overtreatment of patients?

87 screening results to avoid misdiagnosis and overtreatment of persons with isolated clinic hypertensi

88 ecific antigen screening has led to enormous overtreatment of prostate cancer because of the inabilit

89 causes long-term toxicity and may represent overtreatment of some patients.

90 -effectiveness and data addressing potential overtreatment of suspicious skin lesions.

91 ancer that has resulted in overdiagnosis and overtreatment of the disease.

92 improved survival, thereby avoiding systemic overtreatment of these patients.

93 urgently needed to reduce overdiagnosis and overtreatment of this common disease.

94 At the same time, overtreatment of uninfected individuals increases the ri

95 atment intensity over time in order to avoid overtreatment or undertreatment, and the use of supporti

96 DL <100 mg/dL) had higher rates of potential overtreatment (P<0.001).

97 erformance at finding infections, minimizing overtreatment, reducing clinical case counts, and interr

98 To address this potential overtreatment, sentinel lymph node (SLN) biopsy is curre

99 ment, reducing pCRM involvement and avoiding overtreatment through selective preoperative therapy and

100 f all potential organisms, carrying risks of overtreatment, toxicity, and selection of multidrug-resi

101 ert Ultra will likely result in considerable overtreatment unless the possibility of higher specifici

102 l or low-grade pathology when calculation of overtreatment was restricted to patients diagnosed with

103 as lower (with a possibility of no increased overtreatment) when using specificity data only from low

104 persistent high rates of mastectomy suggest overtreatment, whereas lower than expected rates of radi

105 te balance between high cancer cure rate and overtreatment, which could potentially lead to unnecessa

106 Thus, overtreatment with antibiotics is widely prevalent, but

107 only a treat-to-target approach may motivate overtreatment with high-dose statins, potentially leadin

108 These trends suggest that overtreatment with multiple inotropes contributes to the

109 , presumptive treatment leads to substantial overtreatment without additional morbidity reduction und